openPR Logo
Press release

Rosa & Co and Vitalea Science to present at ASPCT 2011 meeting

02-15-2011 09:26 AM CET | Health & Medicine

Press release from: Rosa and Co

In collaboration with Vitalea Science, Inc., Rosa & Co will present a poster at the 2011 American Society for Clinical Pharmacology and Therapeutics in Dallas, TX entitled "Compartmental Analysis of Urosodiol PK in Neonates using AMS " at 8:00 am on March 4, 2011.

One of the reasons for the dearth of clinical drug testing in newborns is a lack of sensitive and non-invasive tools to support clinical trials. Most medicines prescribed to children are done off-label, with dosages extrapolated from adult data through body weight and surface-area calculations. Ursodiol (UDCA), while not approved by the FDA for use in newborns, is used to treat pediatric cholestasis. Measurement of UDCA PK requires differentiating between endogenous and exogenous compound by using a labeled tracer. This is the first clinical study of UDCA pharmacokinetics in a pediatric population. The PK model uses Accelerated Mass Spectrometry (AMS) data in a first of kind study in neonatal ICU patients.

About Rosa & Co
Rosa informs our customer’s most critical decisions – from preclinical through clinical development – with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa’s innovative PhysioPD™ models. With these approaches, Rosa’s clients collaborate in model creation and testing, retain the final model, and acquire the ability to use and interpret it. Rosa’s staff have unparalleled experience in drug-disease modeling and simulation (M&S), spanning hundreds of applications and dozens of clients over close to two decades of professional experience. Rosa is unique in their breadth and depth of disease area experience, including metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory, and antibacterials/antivirals. For more information, visit www.rosaandco.com.

About Vitalea Science
Vitalea Science is a technology-driven Contract Research Organization that provides ultralow detection strategies for drugs and drug candidates at microdose levels. Situated in Northern California, the company was formed by chemists and physicists from the University of California at Davis and the Department of Energy's Lawrence Livermore National Lab in 2003. For more information, visit http://www.vitaleascience.com

Rebecca Baillie
Rosa & Co. LLC
751 Laurel St., Ste. 127,
San Carlos, CA 94070
530-661-7476
rbaillie_rosa@rosaandco.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rosa & Co and Vitalea Science to present at ASPCT 2011 meeting here

News-ID: 162487 • Views:

More Releases for Vitalea

Rosa’s Toufigh Gordi to Present at 2nd Annual Pediatric Pharmacology Conferenc …
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that its Dr. Toufigh Gordi, President of PKPD and Clinical Pharmacology Services, will present the results of an Accelerator Mass Spectrometry (AMS) microdosing study in infants at the 2nd Annual Pediatric Pharmacology Conference in Philadelphia, PA on January 26, 2012. Dr. Gordi will give a 30 minute scientific presentation entitled “Pediatric PK
Rosa Announces Six Poster Presentations at the American College on Pharmacometri …
Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it has six posters scheduled during the 2011 American College on Pharmacometrics (ACoP) meeting in San Diego, CA April 3-6, 2011. The presentations describe the use of PK/PD and physiological modeling in applications from preclinical through clinical development. Five of the posters will be presented in conjunction with Lithera, MediciNova, Pfizer,